Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease
Abstract
Vedolizumab is effective for inducing and maintaining remission in adults with inflammatory bowel disease (IBD); however, there is limited pediatric data. This study aimed to describe the adverse events and clinical response to vedolizumab in refractory pediatric IBD. Disease activity indices, clinical response, concomitant medication use, and adverse events were measured over 22 weeks in an observational prospective cohort study of children...
Paper Details
Title
Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease
Published Date
Oct 1, 2016
Journal
Volume
22
Issue
10
Pages
2425 - 2431
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History